| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016928169 |
| P356 | DOI | 10.1385/MO:19:2:71 |
| P698 | PubMed publication ID | 12180483 |
| P50 | author | Anne Husebekk | Q14407910 |
| Arne Kolstad | Q87777726 | ||
| P2093 | author name string | Tone Nordøy | |
| Ingeborg S Aaberge | |||
| Helvi H Samdal | |||
| Svein Steinert | |||
| Hasse Melby | |||
| P2860 | cites work | Fever in immunocompromised patients | Q33732574 |
| A universal influenza A vaccine based on the extracellular domain of the M2 protein | Q33875466 | ||
| Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination | Q34002520 | ||
| Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection | Q34006372 | ||
| The Prevention of Pneumococcal Disease in Children | Q34408017 | ||
| Minimum Protective Serum Concentrations of Pneumococcal Anti-Capsular Antibodies in Infant Rats | Q34463228 | ||
| Response to influenza immunisation during treatment for cancer | Q35270361 | ||
| Seroconversion after influenza vaccination in patients with lung cancer | Q36620042 | ||
| Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma | Q36641621 | ||
| Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients | Q44060659 | ||
| Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease | Q44258913 | ||
| Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons | Q45751290 | ||
| A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. | Q50686159 | ||
| Influenza immunization of adult patients with malignant diseases | Q50948355 | ||
| Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease | Q57997799 | ||
| Antibody response to influenza immunization in adult patients with malignant disease | Q66956827 | ||
| Influenza in children with cancer | Q69640830 | ||
| Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly | Q70916641 | ||
| Human antibody response to a pneumococcal vaccine in SCID-PBL-hu mice and simultaneously vaccinated human cell donors | Q71233473 | ||
| Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease | Q71555880 | ||
| Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation | Q71841937 | ||
| Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy | Q72770789 | ||
| Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia | Q73414332 | ||
| Immunogenicity of influenza vaccine in patients with hemato-oncological disorders | Q74484107 | ||
| Immunization of transplant recipients | Q77370711 | ||
| Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) | Q81098614 | ||
| P433 | issue | 2 | |
| P921 | main subject | Streptococcus pneumoniae | Q221179 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 71-78 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Medical Oncology | Q2152666 |
| P1476 | title | Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae | |
| P478 | volume | 19 |
| Q34390072 | 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host |
| Q30413413 | A Prospective Study of the Factors Shaping Antibody Responses to the AS03-Adjuvanted Influenza A/H1N1 Vaccine in Cancer Outpatients |
| Q55364518 | Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). |
| Q36367268 | Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). |
| Q26801716 | Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) |
| Q51617424 | Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America |
| Q43764004 | Cost-effectiveness of influenza vaccination in working-age cancer patients |
| Q37771941 | Dendritic cell vaccines for the immunocompromised patient: prevention of influenza virus infection |
| Q27015365 | Development of a vaccine against Staphylococcus aureus |
| Q37475459 | Economic burden of mucormycosis in the United States: can a vaccine be cost-effective? |
| Q54982512 | Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study. |
| Q92088935 | Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly patients with colorectal cancer: A population-based propensity score-matched cohort study |
| Q43490574 | Epidemiology and outcomes of serious influenza-related infections in the cancer population |
| Q33259460 | Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy |
| Q21284664 | Guidelines on vaccinations in paediatric haematology and oncology patients |
| Q40392438 | Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii. |
| Q91771793 | Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial |
| Q100390967 | Impact of 23-valent pneumococcal polysaccharide vaccination on the frequency of pneumonia-related hospitalization and survival in elderly patients with prostate cancer: A seven-year nationwide matched cohort study |
| Q38202580 | Infections associated with solid malignancies |
| Q82821219 | Influenza Vaccination for Terminally Ill Cancer Patients Receiving Palliative Care: A Preliminary Report |
| Q28079486 | Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety |
| Q37416103 | Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses |
| Q34029923 | Influenza vaccination and associated factors among Korean cancer survivors : a cross-sectional analysis of the Fourth & Fifth Korea National Health and Nutrition Examination Surveys |
| Q28740919 | Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective |
| Q24202869 | Influenza vaccines in immunosuppressed adults with cancer |
| Q49500210 | Influenza vaccines in immunosuppressed adults with cancer |
| Q40724238 | Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center |
| Q86272533 | Modeling Dendritic Cell Vaccination for Influenza Prophylaxis: Potential Applications for Niche Populations |
| Q36794824 | Pain management, supportive and palliative care in patients with renal cell carcinoma |
| Q38168902 | Pneumococcal immunization in immunocompromised hosts: where do we stand? |
| Q30416617 | Practices and predictors of 2009 H1N1 vaccination in cancer patients: a nationwide survey in Korea |
| Q98568602 | Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network |
| Q45369267 | Response to influenza virus vaccination during chemotherapy in patients with breast cancer |
| Q30362892 | The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. |
| Q34568939 | Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. |
| Q41987062 | Trends in invasive pneumococcal disease (IPD) in cancer patients after the introduction of 7-valent pneumococcal conjugate vaccine (PCV7): A 20-year longitudinal study at a major urban cancer center. |
| Q38060894 | Using antimicrobial adjuvant therapy in cancer treatment: a review |
| Q91465250 | Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7) |
| Q33798458 | Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity |
| Q35161720 | Vaccines for invasive fungal infections |
| Q24235812 | Vaccines for prophylaxis of viral infections in patients with hematological malignancies |
| Q24245832 | Vaccines for prophylaxis of viral infections in patients with hematological malignancies |
Search more.